GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
-2.62 (-1.68%)
As of 10:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close155.74
Bid151.67 x 800
Ask152.96 x 800
Day's Range151.32 - 158.00
52 Week Range90.14 - 182.23
Avg. Volume450,472
Market Cap4.703B
Beta (3Y Monthly)2.72
PE Ratio (TTM)N/A
EPS (TTM)-9.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est188.42
Trade prices are not sourced from all markets
  • Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
    Zacks1 hour ago

    Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?

    We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.

  • Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?

    Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?

    Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool2 days ago

    3 Top Healthcare Stocks to Buy in April

    GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

  • 5 Marijuana Stocks Wall Street Is Most Bullish On
    Kiplinger2 days ago

    5 Marijuana Stocks Wall Street Is Most Bullish On

    Cannabis and marijuana stocks are an exciting industry right now. According to Cowen & Co.'s Vivien Azer - a pioneer in cannabis-stock analysis - U.S. marijuana sales are set to reach about $80 billion by 2030. Currently, U.S. legal and illicit sales combined total at least $50 billion. That's on top of an estimated $C12 billion in Canadian revenue by 2025 for both recreational and medical use.The problem? It's still early days for the sector, which means significant risk is involved. It's common to see these primarily small- and mid-cap stocks move 10% or more in response to headlines or quarterly earnings reports. Companies are rushing to establish an early leadership position, and not all of them will end up winners. Plus, the federal legalization of cannabis in the U.S. remains a big question mark.So how do you pinpoint the most compelling investing opportunities in this lucrative industry? One option is to focus on the cannabis stocks that the Street is most bullish on right now.We used TipRanks market data to pinpoint five cannabis and marijuana stocks to buy based on overwhelmingly positive consensus ratings among Wall Street analysts. Let's take a closer look at each. SEE ALSO: Goldman Sachs: 7 Growth Stocks to Buy With Explosive Potential

  • How Cannabis Companies’ Upside Potential Stacks Up
    Market Realist2 days ago

    How Cannabis Companies’ Upside Potential Stacks Up

    Why Did Cannabis Stocks Fall on April 15?(Continued from Prior Part)Cannabis stocks Cannabis stocks were deep in the red on April 15. The sector is known for high volatility. Stocks in the cannabis space are more volatile compared to broader

  • Cannabis stocks slammed as Aphria’s quarterly loss weighs on sector
    MarketWatch2 days ago

    Cannabis stocks slammed as Aphria’s quarterly loss weighs on sector

    Cannabis stocks were mostly lower Monday, led down by Aphria Inc. after it swung to a wide loss in the third quarter that overshadowed a surge in revenue.

  • ACCESSWIRE2 days ago

    CBD Company to Research Now

    HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...

  • Why Did Cannabis Stocks Fall on April 15?
    Market Realist2 days ago

    Why Did Cannabis Stocks Fall on April 15?

    Why Did Cannabis Stocks Fall on April 15?Cannabis stocksCannabis stocks were broadly in the red on April 15. Charlotte’s Web Holdings (CWBHF) saw a negative price action of 5.8%. Looking at other stocks, Emerald Health Therapeutics (EMH), Supreme

  • Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?
    Zacks3 days ago

    Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?

    At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool4 days ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Both of these biotech stocks have tremendous momentum. Which is more likely to deliver bigger returns in the future?

  • GW Pharmaceuticals PLC (GWPH) Stock Moves -0.28%: What You Should Know
    Zacks7 days ago

    GW Pharmaceuticals PLC (GWPH) Stock Moves -0.28%: What You Should Know

    In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $171.84, marking a -0.28% move from the previous day.

  • GlobeNewswire7 days ago

    GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Appointment of Darren Cline as U.S. Chief Commercial Officer

    GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced the appointment of Darren Cline as its new U.S. Chief Commercial Officer. Mr. Cline will lead the Epidiolex® U.S. commercial organization and is expected to start on April 22, 2019.

  • 4 Stocks Giving Investors Direct Exposure to CBD
    Motley Fool7 days ago

    4 Stocks Giving Investors Direct Exposure to CBD

    With global CBD sales potentially hitting $22 billion by 2022, here are four CBD stocks you'll want to know about.

  • 9 High-Risk Stocks to Buy for Massive Rewards
    InvestorPlace7 days ago

    9 High-Risk Stocks to Buy for Massive Rewards

    [Editor's note: This story was previously published in November 2018. It has since been updated and republished.]Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.Still, there's room in any investor's portfolio for higher-risk, higher-reward plays -- as long as those risks are understood.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn that vein, here are 10 stocks to buy that offer potentially significant rewards … and almost as much risk. None of these stocks should be a core part of a portfolio, and all have the potential to blow up in your face. * 10 Dow Jones Stocks Holding the Blue Chip Index Back But taking those risks also creates the possibility of a major reward. It's likely at least a few of these stocks will wind up big winners going forward. Teva Pharmaceutical (TEVA)Teva Pharmaceutical (NYSE:TEVA) isn't having a great year, down just about 7%.Teva has too much debt and too little growth. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. Bankruptcy likely isn't a near-term scenario but the current trajectory suggests it could occur down the line. In short, TEVA is a classic contrarian, "buy when there's blood in the streets" type of play. And there are reasons TEVA is one of these great (if risky) stocks to buy.While pressure has persisted on generic drugs, but it won't last forever.The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat. In my opinion, Teva is a better version of Valeant, but with an easier path back to normalcy.It's a risky path, but if it works TEVA could gain another 20%-plus simply by reaching a higher multiple and removing bankruptcy fears.Source: Shutterstock Scientific Games Corp (SGMS)The story already has played out somewhat at Scientific Games (NASDAQ:SGMS), which is up 14.23% so far this year. But the growth story isn't necessarily over.Only a few years ago, Scientific Games was a sleepy, low-growth provider of lottery tickets and terminals. But in quick succession, SciGames acquired slot machine manufacturers WMS Industries and Bally Technologies, the latter coming only months after Bally bought equipment maker and gaming table designer Shuffle Master. Scientific Games became the dominant supplier to the casino industry worldwide: a "one-stop shop" for casino floors.It also became one of the most indebted companies in the U.S. markets and still is. The combination of that debt and careful cost controls at casinos, particularly in the U.S., kept SGMS stock below $20 to start the year. * 8 Risky Stocks to Watch as Earnings Season Kicks Off But it now looks like the long-awaited "replacement cycle" of slot machines is arriving and that could be hugely beneficial for Scientific Games and its smaller, similar rival Everi Holdings Inc (NYSE:EVRI). And considering how much leverage is still on the balance sheet, there's a case for SGMS to clear $100 -- yes, $100 -- if profit growth accelerates.That's not a guarantee, obviously, but it's the nature of highly indebted companies. Leverage is a weight when those companies struggle, and it's a springboard when they grow.Source: Chesapeake Energy Chesapeake Energy (CHK)In the case of Chesapeake Energy Corporation (NYSE:CHK), leverage has been a weight. After optimism about stable energy prices and Chesapeake's improved balance sheet boosted CHK stock in 2017, it was nothing but downhill in 2018. CHK now trades up ,pre than 57% since the beginning of the year. This could be the upswing you've been waiting for.I think CHK is the best, if riskiest, of the stocks to buy on higher energy prices. At the least, Chesapeake has bought itself more time for those prices to work higher. It's also worth pointing out that Chesapeake bonds actually have been rather stable so far this year. Efficiency improvements at the wellhead have lowered costs as well.Chesapeake is a risky play, but the combination of debt on the balance sheet and leverage from higher energy prices mean that with a couple of changes, CHK could soar.Source: Web Summit Via Flickr Splunk (SPLK)Splunk (NASDAQ:SPLK), on the other hand, isn't the cheapest stock in its space or anywhere else. The high-flying "operational intelligence" software provider trades up nearly 30% since the beginning of the year alone.The valuation alone shows the risk in SPLK, which has pulled back from brief early-2014 highs above $100. But since that pullback, SPLK stock actually has been rather stable, as investors give the company time to grow into its valuation.Meanwhile, Splunk continues to be a likely acquisition target, with Cisco (NASDAQ:CSCO) cited as a potential buyer in June and International Business Machines (NYSE:IBM) long thought to be a logical acquirer. * 7 High-Risk Stocks With Big Potential Rewards Splunk is a classic growth stock in that it, too, is high-risk and high-reward. But it looks like one of the better growth stocks to buy in what might be an over-aggressive market at the moment.Source: Shutterstock Ship Finance International (SFL)The shipping space generally has been a "Bermuda Triangle" for investor capital, but Ship Finance International (NYSE:SFL) might be the exception to the rule.There's likely to be some near-term volatility and Ship Finance's dividend, which currently yields 10.95%, could be at risk, but it's still one of those great stocks to buy if you can handle the risk.But this also remains one of the best plays in shipping, available for a modest premium to book value and at low-teens multiple to earnings. The industry alone, and a heavily leveraged balance sheet, both show the risk.But if Ship Finance can make it through some choppy waters over the next few months, there's likely a nice return for shareholders on the other side. GW Pharmaceuticals (GWPH)There's no sector of the market more boom-and-bust than biotech and drug development. GW Pharmaceuticals (NASDAQ:GWPH) doubles down on that volatility by developing its drugs from marijuana.But GW Pharmaceuticals isn't one of those fly-by-night penny stocks to buy based on legalized weed. It's a $2.6 billion pharmaceutical company with a legitimate lead product candidate in Epidiolex, aimed to treat Dravet Syndrome and Lennox-Gastaut Syndrome. Sativex, used to treat multiple sclerosisSativex, used to treat multiple sclerosis spasticity, already is on the market. And another compound has potential uses to fight epilepsy and treat autism spectrum disorders. * 10 Medical Marijuana Stocks to Cure Your Portfolio Like most drug development plays, GWPH is high-risk. But there's reason for investors to hold long-term optimism toward the company's pipeline. Success in getting those drugs to market likely would make GWPH an acquisition target at some point suggesting a significant upside from current levels. If it happens, analysts see GWPH stock surging near 30%.That in turn, would suggest likely significant upside from current levels for GWPH stock.Source: Shutterstock Canadian Solar (CSIQ)Considering that solar power actually is gaining an increasing share of the U.S. market, in particular, it's surprising that solar stocks including Canadian Solar (NASDAQ:CSIQ) actually haven't done all that well. SolarCity had to be rescued by Tesla (NASDAQ:TSLA). First Solar (NASDAQ:FSLR) is down from multi-year highs despite the recent strength.There are risks for CSIQ, in particular. "Commoditization" and price pressure could hit margins. Still, demand for CSIQ equipment is growing, the stock isn't terribly highly valued, and it's lagged of late while FSLR, in particular, has risen.Solar stocks are likely to stay choppy for a while, but CSIQ should have some room to run if it can get through the second half of the year.Source: Helgi Halldorsson via Flickr Superior Industries International (SUP)Superior Industries International (NYSE:SUP) is on the move again. Shipments of the company's aluminum wheels hit a record last year and it's starting to pay off.Auto parts stocks as a whole have had trouble, driven by "peak auto" concerns in the space. Superior itself has had a couple of missteps that impacted margins, and profits. And with SUP one of the more indebted companies in the sector, both factors have had an amplified impact on Superior's share price. * 7 Biometric Stocks to Watch as AI Rises But there's a reason to see a reversal as well, which is what makes SUP one of the smart stocks to buy. Near-term auto sales may be coming down, particularly in the U.S.Last year's acquisition of European supplier UNIWHEELS improved Superior's position overseas. And there is room to improve execution, and hopefully, margins, going forward.SUP does have potential downside risk, particularly if global macro concerns arise, pressuring auto sales and dropping SUP earnings further. But for contrarians who think the auto parts selloff is overdone, SUP is one of the more intriguing plays.Source: Rob Wall via Flickr (Modified) Chegg (CHGG)Chegg (NYSE:CHGG) is another of the growth stocks to buy with a high valuation and a big opportunity. The company began as an online textbook rental company. But it wound up outsourcing that business to another provider and since has focused on becoming the dominant digital platform for U.S. college students.And Chegg is having some success. Revenues are growing and adjusted EBITDA has turned positive after years of losses. The company's tutors and study services businesses are growing rapidly, and it's becoming a fixture in the college landscape.There are risks here beyond valuation. Like so many companies, Amazon is a potential competitor down the line, given its efforts to offer free Prime services to college students. But at this point, it might simply be easier for Amazon to buy Chegg, rather than expend the resources to try and fight it.With each passing quarter, Chegg gets more and more entrenched. And that only serves to strengthen the bull case for CHGG stock.As of this writing, Vince Martin did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Cheap Stocks That Are Leading the Blue Chips * 7 Straight-A Stocks to Build a Portfolio Around * Forget the FANGs -- Buy These 5 Tech Stocks Instead Compare Brokers The post 9 High-Risk Stocks to Buy for Massive Rewards appeared first on InvestorPlace.

  • Benzinga8 days ago

    Bulls And Bud Of The Week: CB2 Insights And Dr. Kerklaan's Therapeutics

    The fact is, there really aren't a lot of quality medical cannabis stocks out there that are taking the “medical” part of all of this seriously. CB2 is essentially implementing traditional health care protocols to the cannabis industry, so it can effectively integrate with the health care industry.

  • Schaeffer's Investment Research9 days ago

    Enormous Put Trade Crosses on GrubHub

    There's also unusual options activity on GWPH and MRVL

  • Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
    Zacks9 days ago

    Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

    Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

  • GW Pharmaceuticals plc (NASDAQ:GWPH): Financial Strength Analysis
    Simply Wall St.9 days ago

    GW Pharmaceuticals plc (NASDAQ:GWPH): Financial Strength Analysis

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like GW Pharmaceuticals plc...

  • Benzinga9 days ago

    FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy

    Zogenix, Inc. (NASDAQ: ZGNX ), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, ...

  • Why Zogenix Stock Is Getting Crushed Today
    Motley Fool9 days ago

    Why Zogenix Stock Is Getting Crushed Today

    The FDA refused to accept the biotech's experimental epilepsy medication for review.

  • Barrons.com9 days ago

    3 CBD Companies That Could Win a ‘Wild West’ Showdown in the Hemp Market

    CBD has been everywhere since Congress decriminalized hemp.The stock market never misses a fad, so public companies are eagerly adding hemp to their product lines.

  • Reuters10 days ago

    Zogenix's seizure drug filing fails to pass U.S. FDA scrutiny

    The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc's treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy. Shares of the California-based drug developer plunged nearly 30 percent to $36.50 after it disclosed the FDA's "refusal to file" letter, which investors could consider as a potential delay in getting approval for the drug. Zogenix's drug, to be branded as Fintepla, uses a low-dose, liquid solution of fenfluramine, which was used in an obesity drug combination that was withdrawn from the market due to evidence of heart valve damage.

  • 4 Marijuana Stocks to Watch in 2019
    Zacks10 days ago

    4 Marijuana Stocks to Watch in 2019

    According to Arcview Market Research and BDS Analytics, global consumer marijuana outlays are estimated to climb 38% to $16.9 billion this year, up from a projected $12.2 billion last year, $9.5 billion in 2017, and $6.9 billion in 2016.

  • Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?
    Zacks10 days ago

    Is GW Pharmaceuticals (GWPH) Stock Outpacing Its Medical Peers This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • 9 Things You Must Know About CBD Before Investing in Pot Stocks
    Motley Fool11 days ago

    9 Things You Must Know About CBD Before Investing in Pot Stocks

    Global CBD sales could soar by 147% annually over the next four years.